Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Comparative real-world outcomes of bispecific antibodies versus pomalidomide-based regimens in relapsed/refractory multiple myeloma: A propensity-matched cohort analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

FKFayaz KhanRoswell Park Comprehensive Cancer CenterZAZuhair AlamUniversity at Buffalo, State University of New York

Discussion

Loading...

Member takes

Overview

Retrospective cohort analysis reveals bispecific antibodies have higher hospitalization and neurotoxicity risks than pomalidomide in relapsed myeloma.

Key Points

  • To compare the effectiveness and safety of bispecific antibodies and pomalidomide-based regimens in relapsed/refractory multiple myeloma.
  • Retrospective cohort study using propensity score matching
  • Included adults ≥18 with relapsed/refractory multiple myeloma
  • Compared outcomes between bispecific antibodies and pomalidomide-based regimens for one year
  • Higher neurotoxicity associated with bispecific antibodies (HR 1.70; p=0.01)
  • Lower neutropenia rates found with bispecific antibodies (HR 0.7; p=0.04)
  • Similar all-cause mortality rates between bispecific antibodies and pomalidomide (HR 1.22; p=0.08)
  • Significantly higher hospitalization risk with bispecific antibodies (HR 2.54; p<0.01)

Cite This Study

Khan et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7c2https://doi.org/10.1182/blood-2025-2211
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1P56 | BASELINE IMMUNE PROFILE PREDICTS RESPONSE TO BISPECIFIC ANTIBODIES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD MONOCENTRIC EXPLORATORY ANALYSIS2026
  2. 2Hematotoxicity and immune deficits with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma2025 · 1 citations
  3. 3Real-world toxicity of bispecific antibodies versus CAR-T cell therapy in diffuse large B-cell lymphoma and follicular lymphoma.2026
  4. 4Safety and Efficacy of Bispecific Antibody Treatment in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Proportions from Clinical Trials2025 · 12 citations
  5. 5Real world outcomes of sequencing bispecific antibodies (BsAb) in patients with relapsed / refractory follicular lymphoma (R/R FL): A multi-center cohort study from cubic consortium2025